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Asparagus (蘆筍 Lú Sǔn; Asparagus officinalis L.)  is a healthy 
and nutritious vegetable that is consumed in many countries. His-
torically, asparagus has been used as a traditional medicine in Chi-
na as an antifebrile and antitussive agent, hair growth stimulator, 
and diuretic agent.[1] A recent study indicated that asparagus and its 
extracts have potential in terms of anti-fungal, anti-dyspeptic, an-
tihypertensive, antidyslipidemic, and antihyperglycemic effects.[2] 
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ABSTRACT
Asparagus (蘆筍 Lú Sǔn; Asparagus officinalis L.) is a common vegetable, long used as an herbal medicine. The cladophylls and 
bottom-stems of asparagus have various pharmacological effects, but they are generally discarded at harvesting. The present open 
clinical trial was performed to examine the effects of the intake of cladophylls and bottom-stems on the improvement of metabolic 
syndrome characterized by hypertension, hyperglycemia, and dyslipidemia. Twenty-eight healthy volunteers ingested either cladophyll 
or bottom-stem powder (6 g/day) daily for 10 weeks. The cladophyll intake resulted in significant reduction in the subjects’ diastolic 
blood pressure and fasting plasma glucose (FPG), and decreased both the left cardio-ankle vascular index score and the total cholesterol 
level (T-CHO). The bottom-stem intake significantly reduced the subjects’ systolic and diastolic blood pressure and FPG as well 
as T-CHO. These results suggest the possibility that asparagus cladophylls and bottom-stems differentially improve hypertension, 
hyperglycemia, and dyslipidemia.
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However, the mechanisms of these effects have not been fully 
elucidated.
Various bioactive compounds, including flavonoids, sterol–sa-
ponins, oligosaccharides, and carotenoids, have been identified in 
asparagus.[3-6] A large amount of rutin was found in asparagus, at a 
level similar to that of buckwheat;[7] rutin is a flavonol glycoside 
composed of the flavonol quercetin and the disaccharide rutinose.[8] 
The main biological activity associated with rutin and quercetin is 
the antioxidant effect through a free radical scavenging capacity.
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[9] It has also been reported that rutin has various effects in vitro 
and in vivo, including anti-inflammatory, antihypertensive, and 
antihyperglycemic effects.[10-12]
The edible shoot of asparagus is about one-half to two-thirds 
of the full length of the stems. When asparagus stems are cropped, 
leaf-like ferns called cladophylls and the remaining woody part 
(the bottom-stem) are removed and discarded as by-products 
because they are tough and difficult to eat. Motoki et al. reported 
that an estimated 130,000 kg of asparagus cladophylls is annually 
discarded as industrial waste.[13] However, the cladophylls contain 
a variety of bioactive substances. Approximately three times the 
amount of rutin was identified in asparagus cladophyll compared 
to the green asparagus stem.[14] It was reported that asparagus 
bottom-stems contain protodioscin, an antitumor substance, at 
a level over 100 times that seen in the green asparagus stems.[15] 
These findings indicate that the by-products of asparagus, such as 
cladophyll and bottom-stem, could be used as the sources of sev-
eral functional ingredients for supplements to improve metabolic 
syndrome, which is characterized by hypertension, hyperglycemia, 
and dyslipidemia.
In this study, we evaluated the effects of asparagus bottom-
stems and cladophylls in human beings by analyzing the biomark-
ers associated with blood glucose metabolism as well as the lipid 
profile in healthy subjects.
METHODS
Study subjects and protocol
The study population consisted of 28 volunteers (14 males 
and 14 females, aged 35–67 years). We recruited those volunteers 
whose body mass index (BMI) ranged from 20 to 30 kg/m2. Among 
them, 17 volunteers were diagnosed as having metabolic syndrome 
or pre-metabolic syndrome according to the diagnostic criteria of 
The Japan Society for the Study of Obesity (JASSO).[16]
None had a history of recent gastrointestinal illness, pregnancy, 
significant disease, surgery, or severe allergic reactions to food, or 
current use of any medications or supplements. The 28 subjects 
were randomly and blindly divided into two treatment groups 
(n = 14 each): the cladophyll group and the bottom-stem group. 
All subjects took 6 g of cladophyll or bottom-stem powder daily 
for 10 weeks. The dosage and follow-up period were determined 
considering the results of both an experimental animal study with 
rats and a pilot clinical trial with human beings (data not shown). 
The subjects were advised to ingest the powder either with a glass 
of water or as an ingredient in their cooking. Measurements of 
blood pressure (BP) and the cardio-ankle vascular index (CAVI) 
score were performed at baseline (0 week), 5 weeks, and 10 weeks 
after the initiation of the powder supplementation. Biomarkers 
for glucose and lipid metabolisms were measured at 0 week and 
10 weeks.
The protocol for this study was approved by the Ethics Com-
mittee for Human Health of Hokkaido Information University, 
and written informed consent was obtained from all subjects. The 
study was carried out in accordance with the ethical principles that 
have their origin in the Declaration of Helsinki.
Test meal preparation
The powdered cladophylls and bottom-stems of green aspara-
gus (蘆筍 Lú Sǔn; Asparagus officinalis L.) harvested in Hokkaido 
were kindly provided by Hokushin Foods Co. Ltd (Ebetsu, Hok-
kaido, Japan). Dry powder of cladophylls was prepared by blanch-
ing, drying and crushing cladophylls in a conventional method. In 
a similar manner, bottom-stem powder was prepared by blanching, 
drying and crushing the bottom-stem, and the powder was mixed 
with trehalose and dextrin (bottom-stem powder:trehalose:dextrin 
= 1:1:7). The production and the packing were carried out in 
Hokushin Foods Co. Ltd, the quality-controlled manufacturing 
plant   in compliance with the Food Sanitation Act (the Ministry of 
Health, Labor, and Welfare of Japan). The quality and safety of test 
samples were thoroughly examined by Hokushin Foods Co. Ltd. 
Measurement of BP and CAVI score
The subjects’ CAVI and BP values were measured at each visit 
under carefully controlled conditions by means of the VaSera CAVI 
instrument (Fukuda Denshi Co., Tokyo, Japan). To measure the 
CAVI, cuffs were placed on both ankles and brachium. In brief, 
CAVI was calculated using the following formula: CAVI = a{(2q/
DP) 9 ln(Ps/Pd)PWV2}+ b, where Ps is the systolic blood pressure 
(SBP), Pd is the diastolic blood pressure (DBP), PWV is the pulse 
wave velocity (Hasegawa’s method), DP is Ps − Pd, q is blood 
density, and a and b are constants.
Statistical analysis
Averages and standard deviations of age and other parameters 
were calculated for each group. Statistical analyses were per-
formed with the program IBM SPSS Statistic 19 (IBM, Armonk, 
NY, USA). Paired t-tests were performed for the data obtained at 
baseline and at 5 weeks and 10 weeks after the supplementation 
started. P-values less than 0.05 were considered as significant.
RESULTS
Effect of cladophyll and bottom-stem on BP
Twenty-seven subjects (13 males and 14 females) completed 
the study; one male subject dropped out due to his irregular diet. 
The clinical characteristics of all subjects are shown in Table 1. 
First, to determine the effect of the cladophyll and bottom-stem 
powder on BP, we measured SBP and DBP. We found that bottom-
stem intake significantly reduced SBP from 143.2 ± 6.1 mmHg to 
Table 1. Characteristics of the subjects in the asparagus bottom-stem 
and cladophyll groups
Characteristic Bottom-stem Cladophyll
Number of subjects 14 13
Age (years) 50.86 ± 10.57 50.38 ± 9.25
Number of males (%) 9 (64.29%) 8 (61.54%)
Body weight (kg) 67.73 ± 10.07 69.06 ± 10.94
Height (cm) 164.18 ± 7.66 164.36 ± 8.58
Body mass index (kg/m2) 25.04 ± 2.85 25.51 ± 3.17
Values shown are mean ± SD. Statistical analysis was performed by paired 
t-test for age, body weight, height, and body mass index, and by chi-square 
test for gender
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135.7 ± 6.5 mmHg (P = 0.031) in 5 weeks after the ingestion and 
from 143.2 ± 6.1 mmHg to 134.6 ± 4.4 mmHg (P = 0.012) in 10 
weeks after the ingestion [Figure 1a]. A significant improvement 
was also observed in DBP after 10 weeks of intake of both clado-
phyll and bottom-stem, showing reduction from 80.6 ± 2.1 mmHg 
to 75.2 ± 2.5 mmHg (P = 0.015) and from 86.0 ± 3.7 mmHg to 
81.4 ± 3.5 mmHg (P = 0.040), respectively [Figure 1b]. Moreover, 
we observed that DBP in 5 weeks after the bottom-stem intake 
was significantly decreased from 86.0 ± 3.7 mmHg (the baseline) 
to 80.1 ± 3.1 mmHg (5 weeks) (P = 0.004).
Effect of cladophyll and bottom-stem powder ingestion on 
CAVI scores
We also examined the subjects’ CAVI scores on both ankles 
and brachium. The CAVI score has been widely accepted as a 
reliable indicator of arterial stiffness.[17] The subjects’ right CAVI 
scores showed little change, but the left CAVI scores appeared 
to be slightly decreased from 7.19 ± 0.19 to 6.95 ± 0.19 after the 
cladophyll intake, which was a non-significant reduction (P = 
0.26) [Figure 2].
Effects of cladophyll and bottom-stem on glucose 
metabolism
We next examined the effects of cladophyll and bottom-stem 
powder ingestion on fasting plasma glucose (FPG) and hemoglobin 
A1c (HbA1c). Although no significant change in the subjects’ HbA1c 
values was observed [Figure 3b], the FPG values were significantly 
decreased by both bottom-stem and cladophyll intake, from 104.1 
Figure 2. Effect of bottom-stem and cladophyll intake on the cardio-ankle vascular index (CAVI) scores. Values are means ± SE. (a) Left CAVI, (b) right 
CAVI. Open circles, bottom-stem subjects (n = 14); closed circles, cladophyll subjects (n = 13)
Figure 1. Changes in the subjects’ blood pressure following the 10-week daily intake of 6 g of asparagus bottom-stem or cladophyll powder. Values 
are means ± SE. (a) Systolic blood pressure (SBP), (b) diastolic blood pressure (DBP). Open circles, bottom-stem subjects (n = 14); closed circles, 
cladophyll subjects (n = 13). *P < 0.05, **P < 0.01
a b
a b
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± 3.7 mg/dl to 100.9 ± 3.4 mg/dl (P = 0.042) and from 109.5 ± 4 
mg/dl to 102.9 ± 2.9 mg/dl (P = 0.037), respectively [Figure 3a].
Effects of cladophyll and bottom-stem on lipid metabolism
We measured the total cholesterol (T-CHO) and triglycerides 
(TG). As shown in Figure 4, we found minimal changes in TG 
levels, but the bottom-stem ingestion significantly decreased the 
T-CHO levels from 240.4 ± 6.5 mg/dl to 227.2 ± 8.3 mg/dl (P = 
0.028). The T-CHO levels also tended to decrease after cladophyll 
intake, from 222.5 ± 8.1 mg/dl to 215.2 ± 9 mg/dl (P = 0.302).
Biomarker levels of liver and renal functions after 
cladophyll and bottom-stem intake
We also examined the subjects’ serum levels of biomarkers 
of liver and renal function. Parameters for liver function, i.e., 
aspartate transaminase (AST), alanine transaminase (ALT), and 
gamma glutamyl transpeptidase (γ-GTP), and those for renal 
function, i.e., blood urea nitrogen (BUN) and creatinine, showed 
minimal changes after the 10-week powder intake, suggesting that 
cladophyll and bottom-stem intake causes no unfavorable effects 
on the liver and kidneys at the dose of 6 g/day.
DISCUSSION
A definition of metabolic syndrome was first provided by the 
World Health Organization (WHO) in 1998.[18] The International 
Diabetes Foundation estimated that approximately 20–25% of 
the world’s adult population has metabolic syndrome.[18] Meta-
bolic syndrome comprises a cluster of metabolic abnormalities 
Figure 3. Changes in blood glucose metabolism produced by the intake of powdered asparagus bottom-stems and cladophylls. Value are means ± SE. 
(a) Fasting plasma glucose (FPG), (b) hemoglobin A1c (HbA1C). Open circles, bottom-stem subjects (n = 14); closed circles, cladophyll subjects (n 
= 13). *P < 0.05
Figure 4. Changes in the subjects’ serum lipid profiles in response to the intake of bottom-stems and cladophylls. (a) Total cholesterol (T-CHO), (b) 
triglycerides (TG). Value are means ± SE. Open circles, bottom-stem subjects (n = 14); closed circles, cladophyll subjects (n = 13). *P < 0.05
a b
a b
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including central obesity and high cholesterol, high SBP or DBP, 
and increased fasting glucose.[19,20] Metabolic syndrome is a risk 
factor for cardiovascular disease, diabetes, and certain cancers.[21]
The intake of nutritionally well-balanced health foods is the 
first clinical intervention to counteract metabolic syndrome. The 
routine intake of certain vegetables has been observed to reduce 
the risk of metabolic syndrome.[22] A number of vegetables with 
potential bioactive components, such as polyphenols, sterols, oli-
gosaccharides, and vitamins, have been investigated with regard 
to antihypertensive, antihyperlipidemic, and antihyperglycemic 
effects.[23] Notably, some researchers have focused on the use 
of by-products of vegetables for supplementation and, thereby, 
evaluated them as a potential functional source.[24]
The results of the present open clinical trial demonstrate the 
potential effect of cladophyll and bottom-stem of asparagus (蘆筍 
Lú Sǔn; Asparagus officinalis L.) in the prevention of hypertension, 
hyperglycemia, and dyslipidemia. We found that cladophyll and 
bottom-stem reduced BP and T-CHO. In particular, a reduction 
in FPG followed the 10-week intake of bottom-stem powder and 
cladophyll powder. These results suggest that asparagus clado-
phyll and bottom-stem have the potential to prevent and improve 
lifestyle diseases.
Hypertension is one of the major risk factors for stroke, con-
gestive heart failure, myocardial infarction, peripheral vascular 
disease, and overall mortality.[25] In the present study, significantly 
reduced DBP or SBP was observed, as demonstrated in Figure 1. 
Matsuda et al. demonstrated that asparagus stem prevented 
hypertension through inhibiting angiotensin-converting enzyme 
(ACE) activity in spontaneously hypertensive rat (SHR) , and 
the 2″-hydroxynicotianamine contained in asparagus would be a 
critical component for this effect. It was also reported that rutin 
improved arterial hypertension in an animal model.[26] To elucidate 
their functionality for these diseases, the quantification of 2″-hy-
droxynicotianamine and rutin contained in the asparagus bottom-
stems and cladophylls used in the present study would be helpful. 
However, more than 10 mmHg difference of SBP between the two 
groups was found at the beginning of the trial (130.23 ± 19.80 
mmHg for cladophylls and 143.21 ± 22.85 mmHg for bottom-
stems, with no significant difference). This difference, even though 
statistically not significant, might influence the bottom-stems group 
show better improvement in SBP than the cladophylls group. In 
this context, further research is required to confirm the effect of 
cladophylls and bottom-stems on the prevention of hypertension.
Diabetes mellitus is caused by dysregulation of blood sugar 
that is characterized by persistent hyperglycemia even during the 
fasting state. A raised fasting serum glucose level is an early sign 
of impaired glucose tolerance that is widely used as a screening 
test for diabetes. Recently, extensive search for natural products 
with the potential to reduce blood glucose has been carried out in 
the field of traditional medicine, because the materials provided 
by traditional medicine are generally considered to be better than 
the currently used pharmaceuticals.[27] In the present study, FBG 
was significantly reduced by cladophyll and bottom-stem intake, 
as shown in Figure 3.
There are some reports of the effect of asparagus in the preven-
tion of hyperglycemia. For example, asparagus intake improved 
insulin secretion and β-cell function in vivo and in vitro.[28] Zhao 
et al. demonstrated that asparagus bottom-stem has hypoglyce-
mic functions in a streptozotocin-induced diabetic rat model.[29] 
These findings suggest that the by-products of asparagus we used 
in this study have similar biological effects in terms of glucose 
metabolism.
We also found that the asparagus bottom-stem intake sig-
nificantly decreased the subjects’ T-CHO levels, and the clado-
phyll intake also reduced the T-CHO levels, to a lesser extent. 
Dyslipidemia, a medical condition characterized by increased 
blood levels of lipids such as cholesterol and TG, is an essential 
component of metabolic syndrome and a predisposing risk fac-
tor for atherosclerosis. It is well recognized that lifestyle factors, 
especially dietary habits, play an important role in preventing 
the progress of dyslipidemia. In a hypercholesteremic rat model, 
Visavadiya et al. (2009) observed that asparagus bottom-stems 
contained food factors useful for the reduction of serum cholesterol 
by increasing the rats’ bile acid production and elevating their 
hepatic antioxidant status.[30] They also pointed out that the potent 
therapeutic phytocomponents present in asparagus bottom-stems, 
e.g., phytosterols, saponins, polyphenols, flavonoids, and ascorbic 
acid, are responsible for the improvement of hypercholesterolemia.
Although we did not investigate the mechanisms responsible 
for the biological activity of asparagus cladophyll and bottom-stem 
in the present study, we observed that T-CHO was significantly 
decreased by the cladophyll and bottom-stem intake. This result 
suggests that the by-products of asparagus could improve meta-
bolic syndrome by reducing serum cholesterol. In addition, the 
cladophyll intake slightly decreased the subjects’ left CAVI scores, 
as shown in Figure 2. CAVI is a blood pressure–independent arte-
rial wall stiffness parameter widely used in clinical studies. Several 
reports have shown that CAVI is associated with atherosclerotic 
disease.[31] Data from the present study and findings from a number 
of earlier studies strongly indicate that cladophyll may improve 
arteriosclerosis via a reduction in serum cholesterol.
In summary, we demonstrated the possibility that asparagus 
bottom-stems and cladophylls can modulate hypertension, hyper-
glycemia, and dyslipidemia in human beings, as shown in Figure 5. 
Although we need to obtain more detailed data including those 
of bioactive components, our observations suggest that the effec-
Figure 5. The potential effect of cladophyll and bottom-stem of asparagus 
for the prevention of hypertension, hyperglycemia, and dyslipidemia
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tive use of asparagus bottom-stems and cladophylls may prevent 
lifestyle-related diseases, and the production of supplements 
containing these functional materials would be beneficial both 
for human beings and to eliminate the waste of these asparagus 
by-products.
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